BU/Haymarket deliver 'PI light' CME

Share this article:
Serial, active learning may be the most powerful, but creating a program that promotes performance improvement in a distance-learning setting poses a challenge. “In a serial program, it's very difficult to get people to do more than one [component],” said Lara Zisblatt, assistant director, Boston University School of Medicine CME.
BU and Haymarket Medical Education, partners on the Practice Circles program, produced an activity with elements of a PI activity but one that didn't require the same time commitment. The initiative, aimed at MDs, PAs and NPs, and had an action plan in the middle enabling participants to see practice changes and enabling them to reflect on improvements. (Disclosure: Haymarket Media publishes MM&M.)
“Even though it didn't fulfill the requirements of a PI CME, it sill has the same architecture—an audit of practice in the beginning, a participation and interventions including creation of an action plan, and a reevaluation at the end,” Zisblatt said.
It also required less time to complete. The grantor was Cephalon, maker of wakefulness drug Nuvigil, and the program was designed to improve diagnosis and management of sleep-wake disorders. Since there is no blood test, for example, to diagnose these disorders, Zisblatt shied away from a full-on PI program. “Instead, what we chose to do was what we consider a ‘PI light,'” she said.
The course generated 562 completed actions—listening to a live teleconference, completing a survey or action plan, etc.—while 22 people did all seven components of the eight-week program. The Alliance for CME gave the accredited program its Award for 2011 Best Industry-Supported CME.
Said Zisblatt: “The good news is [if a participant] did even a single piece of the program, we've been finding that, through the evaluations, they've still been improving part of the practice.”
Share this article:

Next Article in Features

Email Newsletters

More in Features

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...